Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MV-012-968
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and toddlers from respiratory syncytial virus, which is investigating in PII trial for the prevention of respiratory syncytial virus in protect infants and toddlers.
Product Name : MV-012-968
Product Type : Vaccine
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : MV-012-968
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Attenuated COVID-19 Vaccine Recombinant, Live
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines
Details : MV-014-212, the company’s intranasal recombinant live attenuated COVID-19 vaccine is designed for global use to block transmission, provide durable protection, and control SARS-CoV-2 spread and variants.
Product Name : MV-014-212
Product Type : Vaccine
Upfront Cash : Inapplicable
July 27, 2022
Lead Product(s) : Attenuated COVID-19 Vaccine Recombinant, Live
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MV-012-968
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and young children from RSV. Safety data show that MV-012-968 is highly attenuated, with no serious adverse events reported.
Product Name : MV-012-968
Product Type : Vaccine
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : MV-012-968
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MV-012-968
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : With Fast Track Designation, Meissa is eligible for early and frequent interactions with FDA reviewers to discuss all aspects of the clinical development plan for MV-012-968.
Product Name : MV-012-968
Product Type : Vaccine
Upfront Cash : Inapplicable
October 01, 2020
Lead Product(s) : MV-012-968
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MV-014-210
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV
Details : Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands.
Product Name : MV-014-210
Product Type : Vaccine
Upfront Cash : Inapplicable
June 30, 2020
Lead Product(s) : MV-014-210
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable